SUS HPV DNA Test Detects Thousands of High-Risk Cases in Brazil

Since the Unified Health System began distributing molecular HPV screening tests, 9,904 tests have returned positive results for high-risk strains linked to cervical cancer. Out of 153 mil total samples collected across the country considering this year and last year, 93 mil were processed in 2026. The World Health Organization has recommended the DNA-HPV exam since 2013, and the SUS introduced it at the beginning of the year to replace the traditional Papanicolau exam, which continues to be performed in the public health network until the transition is complete according to the 2025 Brazilian Guidelines for Cervical Cancer Screening. The strategy also relies on the Now There Are Experts program to help states and municipalities expand specialized appointments, tests, and procedures for patient diagnosis and follow-up, while health professionals act as multipliers to train primary care teams on the new protocols, INCA guidelines, and care workflows.

Molecular Screening Detects High-Risk HPV Strains Across 26 States

Federal health officials report that the DNA-HPV screening tool is now active in 26 states. The rollout relies on collection kits produced by the Instituto de Biologia Molecular do Paraná, as noted by the Ministério da Saúde. Espírito Santo is expected to receive the new tests before the end of the year once local organization steps finish.

The Paraná State Health Department launched an online tracking panel to monitor local collection sites, test volumes, and regional detection rates for high-risk types such as HPV 16 and 18. This tracking tool gathers information using the Laboratory Environment Manager and the Cancer Information System, and it is already running in 46 Paraná municipalities while rolling out in 210 other cities with a goal of reaching 256 municipalities by the end of 2026. The tool is available on the Sesa website under the Chronic Disease Prevention and Smoking page. We started with the pilot project, we grew, and we have a target to reach 256 municipalities throughout Paraná by the end of the year. Women will have an extremely modern and sensitive test for the early detection of this cancer, stated Neves.

Data From Unicamp Study Shows Diagnostic Age Drops by a Decade

A study conducted by the Center for Integral Women’s Health at the State University of Campinas evaluated screening data from Indaiatuba and found that DNA-HPV testing detects cervical cancer indicators ten years earlier than older methods. While conventional Papanicolau screening flags potential issues at an average age of 49.3 years, the molecular test identifies markers at an average age of 39.6 years.

Priority outreach targets patients aged 30 to 49 who have never been screened or who lack follow-up for three years or more, as well as people aged 50 to 64 with delayed exams and other groups named in Paraná’s organized screening protocol.

Federal projections from the Instituto Nacional de Câncer indicate that Brazil could record roughly 19,3 mil new cases of cervical cancer annually through 2028. Health authorities maintain that early detection through molecular screening pushes potential cure rates above 95%, with opportunistic diagnosis offering up to 100% cure chances.

Frequently Asked Questions About the DNA-HPV Test in Public Clinics

Which health facilities provide the new DNA-HPV screening test?

Patients can access sample collection through professionals at public health clinics known as Unidades Básicas de Saúde across participating states.

What is the recommended screening interval following a negative test result?

A negative DNA-HPV test allows for a five-year interval before the next scheduled collection, streamlining laboratory processing and reducing unsatisfactory samples.

How does vaccination coverage compare with screening efforts?

Federal health data for 2025 shows that national vaccination coverage against HPV reached 87% among girls and 74% among boys aged 9 to 14, exceeding global averages.

Recognizing Symptoms and Warning Signs of Advanced Cervical Cancer

The disease may not show symptoms at first, but certain signs require attention and investigation by a health professional, such as bleeding during or after sexual intercourse, bleeding between menstrual periods, bleeding after menopause, pain during sexual intercourse, and vaginal discharge containing blood or a foul odor. In more advanced cases, additional symptoms can appear, including pelvic pain or lower back pain, severe fatigue, kidney problems, and swelling and pain in the legs, matching an earlier figure where the tumor ranks as the third most common cancer in women nationwide.

More on Brazil: Brazil Holds Presidential Runoff Between Lula and Flávio Bolsonaro